ADC Drugs, Targeted Therapy for Treating Cancer- Fulfill the Potential of ADCs

Antibody drug conjugates are a class of biopharmaceutical drugs designed as a targeted therapy for treating cancer.

ADCs target and kill tumor cells while sparing healthy cells.

ADC is typically composed of a monoclonal antibody covalently attached to a cytotoxic drug via a chemical linker.

ADC combines both the advantages of highly specific targeting ability and highly potent killing effect to achieve accurate and efficient elimination of cancer cells.

Medicilon provides ADC chemistry service, includes payload and linker R&D, antibody-drug conjugation.

In vitro evaluation includes binding assay, internalization, cell cycle and apoptosis analysis, ADC bystander effect etc.

In vivo evaluation includes pharmacodynamics evaluation, pharmacokinetics study, toxicology study of ADC etc.

As of April 2024, Medicilon has successfully assisted clients on the IND approval of 24 ADC drugs and has multiple ADC projects on going.

• 
  ADC R&D Service Platform
  ADC R&D Service Platform

  Each ADC R&D project provides its own challenges due to the varieties in the assembly of ADC molecules. With this in mind, Medicilon promises careful planning, meticulous execution and accurate results achievable because we have many years of practical experience and undertake effective communication with our clients.